Uncategorized
VIDEO: Clinical trials show similarities between ranibizumab, aflibercept in treating DME
SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Marco A. Zarbin, MD, PhD, discusses a review of randomized clinical trials of anti-VEGF agents for treating diabetic macular edema, including RISE, RIDE, VIVID, VISTA, RESTORE, Protocol T and Protocol S. The review found that both aflibercept and ranibizumab were "equally effective" in inducing a two-step regression in diabetic retinopathy, durability of the anti-VEGFs was "almost identical," and incidence of systemic side effects "was comparable" in all the studies, Zarbin said.